CD274 and neoplasm: Overall, these studies suggest that patients with PD-L1 positive HNSCC benefit more from checkpoint inhibitors than patients with PD-L1 negative disease and that looking at the PD-L1 expression in tumor and immune cells combined might be more predictive.